Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Good news imminent, algos show 8+, let's make it happen! Also, who the . uses this platform anymore?
SCAM company, my uneducated friend.
Someone apparently has no idea what they are doing. If you can’t make money on a stock like this on a day like this you are definitely doing something wrong my friend... no offense
Massive dump brought this from $7.25 to $6.11 in less than 1 minute
$1.89 loaded $1.15 that's quite good
1.59 not nice anymore...
very nice :)
2.18 now on patent news.
maybe a run to 3.00 tomorrow for a short. Robinhooders will chase anything.
Watching to see if I can pick up some in the .5's. We shall see. Best to all here.
What does this say? From OTCMarkets: IMMP Outstanding Shares 30,260,827
From TDA. Does this not say....IMMP Shares Outstanding 33.4M??
DOES THIS NOT SAY 3.03 BILLION https://finance.yahoo.com/quote/IMMP/key-statistics?p=IMMP
TDA shows 33 million. Where do you see 3 billion?
Immutep to Present at Upcoming Industry Conferences
Tue February 26, 2019 8:00 AM|GlobeNewswire|About: IMMP
SYDNEY, Australia, Feb. 27, 2019 (GLOBE NEWSWIRE) -- Immutep Limited (IMMP) (Immutep (PRRUF) or the Company), a biotechnology company developing novel immunotherapy treatments for cancer and autoimmune diseases, today announced its participation in various upcoming industry conferences.
The Company will be presenting updated clinical data from the Phase I TACTI-mel trial in metastatic melanoma for its lead product candidate eftilagimod alpha (“efti” or “IMP321”) and new data relating to its pre-clinical product candidate, IMP761, a novel anti-LAG-3 agonist antibody for the treatment of auto-immune diseases, at industry conferences in March 2019.
Conference:
World Immunotherapy Congress USA 2019
Dates: 3-5 March 2019
Venue: Grand Hyatt, San Diego, USA
Presentation Title:
Two ACTive Immunotherapies (TACTI): Results of a Phase I trial with metastatic melanoma patients
Presenter:
Dr. Frédéric Triebel, CSO and CMO of Immutep
Conference:
14th Congress (CACOX) of ECCO (European Crohn’s and Colitis Organisation)
Dates: 6-9 March 2019
Venue: Bella Center, Copenhagen, Denmark
Presentation Title:
IMP761, a novel anti-LAG-3 agonist antibody for the treatment of auto-immune diseases
Presenter:
Mathieu Angin, Phd, Immutep Research Scientist
All presentations will be made available on the Company’s website.
About Immutep
Immutep is listed on the Australian Stock Exchange (IMM), and on the NASDAQ (IMMP) in the US.
Further information can be found on the Company’s website www.immutep.com or by contacting:
U.S. Investors:
Jay Campbell, Chief Business Officer, Immutep Limited
+1 (917) 860-9404; jay.campbell@immutep.com
Australian Investors/Media:
Matthew Gregorowski, Citadel-MAGNUS
+61 2 8234 0105; mgregorowski@citadelmagnus.com
U.S. Media:
Garth Russell, LifeSci Advisors
+1 (646) 876-3613; garth@lifesciadvisors.com
Source: Immutep Limited 2019 GlobeNewswire, Inc.
https://seekingalpha.com/pr/17424272-immutep-present-upcoming-industry-conferences
Current FDA clinical trials:
https://clinicaltrials.gov/ct2/results?term=Eftilagimod+Alpha++LAG-3Ig+or+IMP321&Search=Search
A drug that activates the protein LAG-3 (Lymphocyte Activation Gene-3) used to increase immune response to tumors and treat end-stage breast cancer.
Eftilagimod alpha (LAG-3Ig or IMP321)
https://thehealthhorizon.com/showcases/innovations/846297b8-898f-43bd-99c9-4c843a4f8cbf
IMMP SEC Suspension:
http://www.sec.gov/litigation/suspensions/2013/34-70784.pdf
Order:
http://www.sec.gov/litigation/suspensions/2013/34-70784-o.pdf
Admin Proceeding:
http://www.sec.gov/litigation/admin/2013/34-70785.pdf
Immtech Appoints Blythe Weigh as Strategic Advisor
Wednesday February 13, 6:30 am ET
NEW YORK, Feb. 13 /PRNewswire-FirstCall/ -- Immtech Pharmaceuticals, Inc. (the "Company") (Amex: IMM - News) is pleased to announce the appointment of leading corporate communications specialist Blythe Weigh Communications (Blythe Weigh) as strategic advisor to the Company (www.blytheweigh.com).
Cecilia Chan, Vice Chairman of Immtech, stated, "We are delighted to have Blythe Weigh join our PR/IR team as we expand our growth opportunities in China and in other key markets."
Founder Tim Blythe has over 25 years of experience in international public relations, spanning media relations, investor relations and government affairs. He will be the lead for Blythe Weigh on the Immtech account.
Mr. Blythe began his career as a press secretary for the British Government in 1982, working for a number of Secretaries of State including Norman Tebbitt, Norman Lamont, Lord Young and Kenneth Clarke. He worked on the privatizations of British Telecom, British Steel, and British Leyland (Rover Group).
In 1988 Mr. Blythe joined the NatWest Group plc where he was head of public relations and was in charge of the bank's reputation around the world. In 1993 he joined Brunswick Group, a specialist financial PR and IR consultancy, where his clients included Astra Zeneca, Barclays Bank and a number of international utilities companies. In 1996, he joined WH Smith Group plc (a client) on their Executive Board as Director of Corporate Affairs.
This was followed by a period at Rolls-Royce Group plc as director of corporate affairs, responsible for global media relations, IR, government relations, staff communications, advertising and managing teams in the UK, USA, Scandinavia, Germany, India and Hong Kong.
In 2004, he returned to consultancy with Beattie Communications. In 2007, Mr. Blythe led the management buy out which launched Blythe Weigh Communications.
Paul Weigh joined Mittal Steel (now Arcelor Mittal) the world's largest steel company, in 1999, spending seven years with that firm. He left as deputy head of corporate communications, after the $42bn merger with Arcelor was successfully completed in 2006.
During his time with Mittal, Mr. Weigh was responsible for coordinating and implementing group communications at the corporate level, including the development of communication strategies to support the Group's expansion into Central and Eastern Europe (acquisitions in Romania, Czech Republic, Poland, Macedonia and Bosnia totaling in excess of $5bn), South Africa (acquisition of Iscor), North America ($4.5bn acquisition of ISG), China and India.
Immtech Investor Conference Call Scheduled for January 3, 2008, at 1 PM
69 minutes ago - PR Newswire
Immtech Pharmaceuticals, Inc. (Amex: IMM) will hold an investor conference call on Thursday, January 3, 2008, at 1 PM (ET) to present an update on the Company's safety study for pafuramidine, the Company's oral drug candidate. Investors and interested parties in the U.S. are invited to join the call by dialing (888) 338-8374 and callers outside the U.S. should call (706) 902-3163. The User Access Code is #29746958. To register, please call no later than 10 minutes prior to the scheduled start of the call. Information to access a recording of the conference call will be available starting on January 10, 2008 from the Immtech Pharmaceuticals website (http://www.immtechpharma.com).
About Immtech Pharmaceuticals, Inc.
Immtech Pharmaceuticals, Inc. is focused on developing and commercializing drugs to treat infectious diseases, and the Company is expanding its targeted markets by applying its proprietary pharmaceutical platform to treat other disorders. Immtech has advanced clinical programs that include new oral treatments for pneumocystis pneumonia (PCP), trypanosomiasis (HAT or African sleeping sickness), malaria and a well defined, expanding library of compounds targeting drug-resistant Gram-positive bacteria, fungal infections, Hepatitis C and other serious diseases. Immtech holds the exclusive worldwide licenses to certain patents, patent applications and technology for products derived from a proprietary pharmaceutical platform. For additional information, please visit the Company's website at http://www.immtechpharma.com
This press release contains forward-looking statements regarding Immtech Pharmaceuticals, Inc.'s business, including the future prospects for PCP. Except for historical information, the matters discussed in this press release are forward-looking statements and are subject to risks and uncertainties. Actual results could differ materially from these forward-looking statements. Factors that could cause or contribute to such differences include, but are not limited to, the following: (i) Immtech's ability to develop commercially viable products; (ii) Immtech's ability to achieve profitability; (iii) Immtech's ability to retain key personnel; (iv) the ability of Immtech's scientists and collaborators to discover new compounds; (v) the availability of additional research grants; (vi) Immtech's ability to obtain regulatory approval of its drug candidates, including PCP; (vii) the success of Immtech's clinical trials; (viii) dependence upon and contractual relationship with partners; (ix) Immtech's ability to manufacture or to contract with a third party to manufacture its drug candidates at a reasonable cost; (x) Immtech's ability to protect its intellectual property; (xi) competition and alternative technologies; (xii) Immtech's ability to obtain reimbursement from third party payers for any product it commercializes; and (xiii) Immtech's potential exposure to significant product liability.
Additional risks are discussed in Immtech's current filings with the Securities and Exchange Commission. Although Immtech believes the expectations reflected in such forward-looking statements are based on reasonable assumptions, it can give no assurance that its expectations will be attained. The forward-looking statements are made as of the date of this press release, and we undertake no obligation to publicly update or revise any forward- looking statement, whether as a result of new information, future events or otherwise, except as required by law.
SOURCE Immtech Pharmaceuticals, Inc.
http://www.immtechpharma.com
Shares of Immtech Pharmaceuticals Inc. (IMM) were on the rebound, up 10% to $2.38. The stock lost almost half its value earlier in the week after Immtech said it was temporarily halting Phase III testing of its drug parfuramidine over safety concerns. The company has been testing the drug against a certain type of pneumonia that commonly strikes AIDS patients.
Immtech has been co-developing parfuramidine with Par Pharmaceutical Cos. (PRX). Shares of Par were down almost 3% to $23.72.
Probably not a golden drug....
http://biz.yahoo.com/prnews/071226/nyw020.html?.v=101
Immtech Announces Interim Analysis in Phase III African Sleeping Sickness Trial
Data Safety Monitoring Board Recommends Continuing Study
NEW YORK, Oct. 4 /PRNewswire-FirstCall/ -- Immtech Pharmaceuticals, Inc. (Amex: IMM) announced today the completion of interim analysis of its Phase III pivotal clinical trial of Immtech's oral drug candidate, pafuramidine. An independent Data Safety Monitoring Board (DSMB) conducted the interim analysis and recommended that the trial should continue as planned. The trial is evaluating the safety and tolerability of pafuramidine, and comparing pafuramidine's efficacy to pentamidine, a non-oral drug, in treating Human African Tryanosomiasis (HAT), also know as African sleeping sickness.
African sleeping sickness is a fatal, vector-borne parasitic disease spread by tsetse flies that threatens approximately 60 million people in sub- Saharan Africa. Current treatments for the first stage of the disease include pentamidine and suramin. Both of these intravenous drugs are associated with reported toxic side effects. If approved, pafuramidine could become the first safe and effective oral treatment for first-stage African sleeping sickness.
Carol Olson, MD, PhD, Immtech's Sr. Vice President and Chief Medical Officer stated, 'Successfully completing pafuramidine's Phase III interim analysis is a major milestone on the path to registering pafuramidine for treatment of African sleeping sickness. The next major milestone will be to have the remaining patients complete the 12-month follow up protocol and for Immtech to prepare the documents for the NDA submission. We aim to have pafuramidine approved to combat this devastating infectious disease.'
Enrollment in this trial was completed earlier in 2007, and all patients are expected to complete the 12-month follow up, which is the primary endpoint for the trial, in second quarter 2008. Subject to having favorable primary analysis results, Immtech plans to submit a New Drug Application (NDA) to the US Food and Drug Administration in the second half of 2008. The FDA has agreed to consider 'accelerated approval' of the 12-month data. The 24-month follow up data will be submitted later to fulfill requirements. The FDA has also granted to pafuramidine's African sleeping sickness indication Fast Track and Orphan Drug status, which is expected to accelerate review and provides for waiver of the Prescription Drug Users Fee.
The interim analysis was specified in the clinical trial protocol to evaluate the efficacy of pafuramidine compared to pentamidine, as well as the safety and tolerability of pafuramidine. The interim analysis was performed after half of the enrolled patients had completed the 12-month follow up protocol. The DSMB reviewed the data in an unblinded manner. However, the sponsor, Immtech, is blinded to the results until all patients have completed the 12-month follow up protocol.
A DSMB is a committee of physicians, scientists, and at least one non- scientific member who review clinical trial data in order to ensure protection of participants and to provide scientific and medical oversight for the trial. The DSMB operates under a trial-specific Charter and also according to the trial protocol. The DSMB could recommend discontinuing a trial if they observe any significant safety or efficacy problems for the test drug. The Charter also allows the DSMB to recommend halting the trial if enrollment is inadequate to complete the trial in a timely manner.
this is huge imo,
inhibits Cancers enzymes......this could be the golden drug!!
Furamidine Found to Inhibit a Key Enzyme Involved in Cancer Cell DNA Repair Mechanisms
NEW YORK, Aug. 14 /PRNewswire-FirstCall/ -- Immtech Pharmaceuticals, Inc. (Amex: IMM) commented today on a recent paper published in Nucleic Acids Research by a group of researchers at the National Cancer Institute on the ability of furamidine to inhibit a key enzyme involved in the DNA repair process (see Note below). Furamidine is the active metabolite (DB75) of Immtech's proprietary, orally bioavailable prodrug, pafuramidine. Of interest is furamidine's potential to inhibit DNA repair in cancerous cells that have been damaged by chemotherapy agents. Furamidine may thus synergistically and selectively enhance the antiproliferative effects of the classes of anticancer agents known as topoisomerase 1 or 2 (Top1, Top2) inhibitors.
This paper highlights a new high-throughput assay for evaluating potential tyrosyl-DNA phosphodiesterase (Tdp1) inhibitors and the activity of furamidine as a low micromolar inhibitor of the enzyme. Furamidine was one of the most potent compounds to come from screening a set comprising of 1981 compounds. The screening was part of the NCI-Development Therapeutics Program.
The authors note that functionally, Tdp1 is part of the DNA repair complex that resolves the irreversible Top1-DNA cleavage complexes by catalyzing the hydrolysis of 3'-phosphotyrolsyl bonds. They further suggest that a Tdp1 inhibitor could act synergistically with the Top1 inhibitors. Earlier work implicates Tdp1 in the repair of Top2-mediated DNA damage. Top2 inhibitors represent another class of anticancer agents where a Tdp1 inhibitor may produce a synergistic response.
Eric L. Sorkin, Immtech's Chairman and Chief Executive Officer, stated, 'We commend the authors for their efforts. At Immtech, we too continue to explore expanding the potential applications of our dications for novel therapeutic uses.'
Note: Smitha Antony et al., Oxford Journals, June 18, 2007, 'Novel high- throughput electrochemiluminescent assay for identification of human tyrosyl- DNA phosphodiesterase (Tdp1) inhibitors and characterization of furamidine (NSC305831) as an inhibitor of Tdp1,' Nucleic Acids Research, http://nar.oxfordjournals.org/, Copyright (C) 2007 Oxford University Press.
David Fleet Joins Immtech Board of Directors
NEW YORK, Aug. 28 /PRNewswire-FirstCall/ -- Immtech Pharmaceuticals, Inc. (AMEX: IMM) is pleased to announce that David Fleet has joined the Company's Board of Directors. Mr. Fleet has over 35 years of experience in the international pharmaceutical industry with proven success in business development, sales and marketing, manufacturing and technical roles in the U.S., Japan, Europe, and the Middle East. He has consulted for King Pharmaceuticals, Inc., Aspen Pharmacare Ltd., Living Cell Technologies Ltd., and Trigen AG. Mr. Fleet has also consulted for Vestar Capital Partners, MPM Capital, Bear Stearns, and Warburg Pincus, and he is a Non-Executive Director of OnMedica Group Ltd., a leading European physician internet website.
Mr. Fleet stated, 'I am impressed by Immtech's achievements and excited by the Company's growth opportunities. I look forward to working closely with the Immtech team to enhance shareholders' value.'
From 1997 to 2002 Mr. Fleet was SVP of Global Business Development for Innovex Ltd. - Quintiles Transnational. In that role he was responsible for global business development across all services and led more than 10 global account teams for major pharmaceutical customers. From 1993 to 1996 he was a founding shareholder of Innovex, responsible for global business development and establishment of principal subsidiaries in Germany, the U.S., and Japan. Mr. Fleet also spent 10 years at Schering-Plough, where he was responsible for various operations, including development and growth of the ethical and OTC products business as Area Director for Middle East and Africa. He was also manager of Schering-Plough's third largest pharmaceutical plant in Europe with responsibility for manufacturing operations for a full range of pharmaceutical products.
Mr. Fleet began his career at Ward Blenkinsop & Co., Ltd., a division of Boehringer Ingelheim, and was also with Major & Company Manufacturing, where he had managerial responsibilities over multiple pharmaceutical plants with large local and expatriate staff in West Africa. In addition to Mr. Fleet's global business development and management skills, he has extensive experience in negotiating with government agencies including the Department of Health from the United Kingdom, and European, Middle East and African Ministries of Health.
Eric L. Sorkin, Immtech's Chairman and Chief Executive Officer, stated, 'We are delighted to have David join the Immtech Board. His track record and extensive knowledge of the pharmaceutical industry make him an ideal addition to our team.'
US FDA Grants Orphan Drug Status to Immtech's Pafuramidine for Treatment of African Sleeping Sickness
NEW YORK, Sept. 19 /PRNewswire-FirstCall/ -- Immtech Pharmaceuticals, Inc. (Amex: IMM) announced today that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation to pafuramidine (DB289) for treating Human African Trypanosomiasis (HAT), also known as African sleeping sickness. Orphan drug designation provides Immtech with numerous financial and regulatory benefits during pafuramidine's development, including government grants for conducting clinical trials, waiver of New Drug Application submission fees, tax credits, and a seven-year market exclusivity upon final FDA approval.
Pafuramidine is currently in phase III clinical trials for African sleeping sickness at six trial sites in Africa. The infectious disease, spread by tsetse flies, threatens approximately 60 million people in over 30 countries in sub-Saharan Africa. Current treatments for the disease are associated with high levels of toxicity and are difficult to administer. Safety data for pafuramidine has been positive to date, and the FDA and Ethics Committees responsible for the study oversight currently allow adolescents, pregnant women and nursing mothers to participate in these clinical trials. These groups are particularly vulnerable to the disease.
'The FDA's decision reflects the significant need for new treatments for African sleeping sickness,' stated Carol Olson, MD, PhD, Immtech's Sr. Vice President and Chief Medical Officer. 'Pafuramidine has the potential to be the first oral treatment for this fatal and neglected disease. Patients often put off screening and treatment because current drugs must be given by injection. A safe and effective pill that is readily available should facilitate cure for more patients in the early stage of the disease. Because pafuramidine is more user-friendly than existing therapies, we anticipate that it would be available in community clinics as well as at current African sleeping sickness treatment centers. Patients could be treated close to home, rather than traveling long distances to specialized centers.'
Pafuramidine has previously been granted Orphan Drug Designation for treatment of pneumocystis pneumonia (PCP) and malaria. In addition to trials for African sleeping sickness, pafuramidine is currently in Phase III clinical trials for PCP, and in Phase II trials targeting malaria treatment and malaria prophylaxis.
'This is another positive milestone for Immtech as pafuramidine advances towards commercialization,' commented Eric L. Sorkin, Immtech's Chairman and Chief Executive Officer. 'We will continue to work closely with our consortium of scientists, and global collaborators to develop safer and more effective therapies for this and other global health threats.'
Chinese SFDA Grants Immtech Fast Track Status
NEW YORK, Sept. 27 /PRNewswire-FirstCall/ -- Immtech Pharmaceuticals, Inc. (Immtech) (Amex: IMM) announced today that the State Food and Drug Administration of the People's Republic of China (SFDA) has granted Immtech's application Fast Track Status for conducting a Phase III clinical trial with pafuramidine, the Company's oral drug candidate for the treatment of Pneumocystis pneumonia (PCP). Pafuramidine is among the first drugs to be considered for Fast Track Status under new and more stringent SFDA rules recently introduced in China. The PCP clinical trial to be conducted in China will be under the US FDA protocol (www.sfda.gov.cn).
Eric L. Sorkin, Chairman and Chief Executive Officer of Immtech stated, 'This is a significant milestone for Immtech to work in China to accelerate the approval and availability of pafuramidine as a treatment for PCP. As the most populous nation in the world, China is well positioned to support and benefit from important efforts to combat PCP and other devastating infectious diseases.'
PCP is a fungal infection in the lungs and can cause potentially life-threatening pneumonia in patients with HIV and other immune-related diseases. An estimated one million adults and children are afflicted with PCP worldwide, and approximately five million more receive prophylaxis.
PCP is one of the most common opportunistic infections in the estimated 42 million AIDS/HIV patients worldwide. There are only a few treatment options for PCP, and patient intolerance of current therapies is a significant problem. In addition, molecular evidence suggests that resistance of Pneumocystis fungus to current therapy is increasing and may result in failure of treatment or prophylaxis. Pending approval to proceed by the Chinese regulatory authority, pafuramidine will be the first drug candidate to advance to clinical stage development in China for HIV related PCP.
Carol Olson, MD, PhD, Immtech's Sr. Vice President and Chief Medical Officer, stated, 'We are enthusiastic about the opportunity to conduct clinical trials in China. International collaboration will be an essential element in global efforts to treat infectious diseases, and we look forward to working closely with China's Centers for Disease Control and other health organizations to bring safe and effective drugs to market.'
In June 2007, Immtech entered into an exclusive licensing agreement with Par Pharmaceutical Companies, Inc. (NYSE: PRX) under which Par will receive commercialization rights in the U.S. to pafuramidine for the treatment of PCP in AIDS patients.
About Immtech Pharmaceuticals, Inc.
Immtech Pharmaceuticals, Inc. is developing and commercializing drugs to treat infectious diseases. Immtech has advanced clinical programs that include new oral treatments for Pneumocystis pneumonia (PCP), malaria, and trypanosomiasis (African sleeping sickness), and a well defined, expanding library of compounds targeting Hepatitis C, fungal infections, and bacterial infections. Immtech holds exclusive worldwide licenses to certain patents, patent applications and technology for products derived from a proprietary pharmaceutical platform. For additional information, please visit http://www.immtechpharma.com.
http://www7.nationalgeographic.com/ngm/0707/feature1/
Pretty good reading on Malaria, it's an ever-increasing problem
Followers
|
2
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
39
|
Created
|
09/29/07
|
Type
|
Free
|
Moderators |
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |